Maurice B Fluitt1,2, Namita Kumari3, Gail Nunlee-Bland1,2,4, Sergei Nekhai3,5, Kanwal K Gambhir1,2,4,5. 1. Genetics and Human Genetics, Howard University College of Medicine, Washington, DC 20059, USA. 2. Molecular Endocrinology Laboratory, Department of Medicine, Howard University College of Medicine, 2041 Georgia Ave, NW, Suite 5C02, Washington, DC 20060, USA. 3. The Center for Sickle Cell Disease, Howard University, Washington, DC 20059, USA. 4. Howard University Diabetes Treatment Center, 2041 Georgia Ave, NW First Floor, Suite 1-OP-97, Washington, DC 20060, USA. 5. Department of Medicine, Howard University College of Medicine, Howard University, Washington, DC 20059, USA.
Abstract
AIMS: The use of circulatory miRNAs as biomarkers and therapeutic targets for T2DM is an explosive area of study. However, no study has investigated circulatory miRNA expression exclusively in African-American adults. The aim of this study was to identify the expression of nine selected miRNAs in erythrocytes of pre-diabetic and type 2 diabetic African-American adults. MAIN METHODS: Patients were recruited from the Howard University Hospital Diabetes Treatment Center following an 8 to 10 hour overnight fast. Expression of the nine selected miRNAs (miRNA-499, miRNA-146, miRNA-126, miRNA-223, miRNA-15a, miRNA-15b, miRNA-224, miRNA-326, and miRNA-375) was evaluated using quantitative real time PCR. KEY FINDINGS: miRNA-15a, miRNA-15b, and miRNA-499 were significantly reduced in erythrocytes of pre-diabetic African-American adults. In the T2DM group, we found significant correlations between miRNA-15a and BMI (r=0.59, p=0.04), miRNA-15a and weight (r=0.52, p=0.01), and miRNA-15b and diastolic blood pressure (r=-0.52, p=0.02). In the pre-diabetic group, we found significant correlations between miRNA-15b and weight (r=0.90, p=0.02) and miRNA-499 and HbA1c (r=-0.89, p=0.01). SIGNIFICANCE: To our knowledge, this is the first study investigating miRNA expression in erythrocytes of non-diabetic high-risk obese--pre-diabetic and type 2 diabetic African-American adults. The findings of this study are consistent with previous reports of reduced expression of miRNA-15a, miRNA-15b, and miRNA-499 in human plasma or serum and in animal models. The current findings support the use of circulating miRNA-15a, miRNA-15b, and miRNA-499 as potential biomarkers for T2DM in African-American adults.
AIMS: The use of circulatory miRNAs as biomarkers and therapeutic targets for T2DM is an explosive area of study. However, no study has investigated circulatory miRNA expression exclusively in African-American adults. The aim of this study was to identify the expression of nine selected miRNAs in erythrocytes of pre-diabetic and type 2 diabetic African-American adults. MAIN METHODS: Patients were recruited from the Howard University Hospital Diabetes Treatment Center following an 8 to 10 hour overnight fast. Expression of the nine selected miRNAs (miRNA-499, miRNA-146, miRNA-126, miRNA-223, miRNA-15a, miRNA-15b, miRNA-224, miRNA-326, and miRNA-375) was evaluated using quantitative real time PCR. KEY FINDINGS: miRNA-15a, miRNA-15b, and miRNA-499 were significantly reduced in erythrocytes of pre-diabetic African-American adults. In the T2DM group, we found significant correlations between miRNA-15a and BMI (r=0.59, p=0.04), miRNA-15a and weight (r=0.52, p=0.01), and miRNA-15b and diastolic blood pressure (r=-0.52, p=0.02). In the pre-diabetic group, we found significant correlations between miRNA-15b and weight (r=0.90, p=0.02) and miRNA-499 and HbA1c (r=-0.89, p=0.01). SIGNIFICANCE: To our knowledge, this is the first study investigating miRNA expression in erythrocytes of non-diabetic high-risk obese--pre-diabetic and type 2 diabetic African-American adults. The findings of this study are consistent with previous reports of reduced expression of miRNA-15a, miRNA-15b, and miRNA-499 in human plasma or serum and in animal models. The current findings support the use of circulating miRNA-15a, miRNA-15b, and miRNA-499 as potential biomarkers for T2DM in African-American adults.
Authors: Matthew N Poy; Jean Hausser; Mirko Trajkovski; Matthias Braun; Stephan Collins; Patrik Rorsman; Mihaela Zavolan; Markus Stoffel Journal: Proc Natl Acad Sci U S A Date: 2009-03-16 Impact factor: 11.205
Authors: Dwi Setyowati Karolina; Arunmozhiarasi Armugam; Subramaniam Tavintharan; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan Journal: PLoS One Date: 2011-08-01 Impact factor: 3.240
Authors: Mathieu Latreille; Karolin Herrmanns; Neil Renwick; Thomas Tuschl; Maciej T Malecki; Mark I McCarthy; Katharine R Owen; Thomas Rülicke; Markus Stoffel Journal: J Mol Med (Berl) Date: 2015-05-28 Impact factor: 4.599
Authors: Jette Bork-Jensen; Camilla Scheele; Daniel V Christophersen; Emma Nilsson; Martin Friedrichsen; Denise S Fernandez-Twinn; Louise G Grunnet; Thomas Litman; Kim Holmstrøm; Birgitte Vind; Kurt Højlund; Henning Beck-Nielsen; Jørgen Wojtaszewski; Susan E Ozanne; Bente K Pedersen; Pernille Poulsen; Allan Vaag Journal: Diabetologia Date: 2014-11-19 Impact factor: 10.122
Authors: Petra Leidinger; Christina Backes; Indra N Dahmke; Valentina Galata; Hanno Huwer; Ingo Stehle; Robert Bals; Andreas Keller; Eckart Meese Journal: Oncotarget Date: 2014-10-15
Authors: Elena Flowers; Juan-Daniel Ramírez-Mares; Marion Velazquez-Villafaña; Ruben Rangel-Salazar; Anatol Sucher; Alka M Kanaya; Bradley E Aouizerat; Maria Luisa Lazo de la Vega Monroy Journal: Int J Diabetes Dev Ctries Date: 2021-02-11